Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas

Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):743-9. doi: 10.1016/s0360-3016(01)01503-6.

Abstract

Purpose: To analyze the results with involved-field radiotherapy after aggressive lymphomas had decreased in size by 50-99% in response to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy.

Methods and materials: From 1988 through 1996, 294 previously untreated patients with Working Formulation intermediate-grade or large-cell immunoblastic lymphomas underwent CHOP-based chemotherapy on 2 consecutive protocols at the M. D. Anderson Cancer Center. Forty-four (15%) of these patients achieved, based on international working group guidelines, a partial (50-75%) response (n = 25), or unconfirmed complete (76-99%) response (n = 19) to a median of 6 cycles of chemotherapy. These patients were treated with salvage involved-field radiotherapy (n = 32) or chemotherapy (n = 12), e.g., MINE-ESHAP, without autologous stem-cell rescue (ASCR).

Results: Median follow-up was 43 months. Partial responders experienced similar outcomes to unconfirmed complete responders. Local control (4-year rates: 86% vs. 53%, p = 0.009) and progression-free survival (4-year rates: 67% vs. 8%, p < 0.0001), but not overall survival (4-year rates: 70% vs. 50%, p = 0.067) were significantly better in those who received salvage radiotherapy, which was well tolerated.

Conclusion: Progression-free and overall survival in aggressive lymphoma patients who underwent salvage radiotherapy were similar to results reported for high-dose chemotherapy with ASCR. The role of salvage radiotherapy in partial and unconfirmed complete responders to CHOP chemotherapy justifies examination in a large, cooperative group trial.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Disease-Free Survival
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Humans
  • Ifosfamide / administration & dosage
  • Lymphoma, Large-Cell, Immunoblastic / drug therapy*
  • Lymphoma, Large-Cell, Immunoblastic / radiotherapy*
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / radiotherapy*
  • Mesna / administration & dosage
  • Methylprednisolone Hemisuccinate / administration & dosage
  • Middle Aged
  • Mitoxantrone / administration & dosage
  • Prednisone / administration & dosage
  • Retrospective Studies
  • Salvage Therapy
  • Vincristine / administration & dosage

Substances

  • Cytarabine
  • Methylprednisolone Hemisuccinate
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Mitoxantrone
  • Mesna
  • Cisplatin
  • Ifosfamide
  • Prednisone

Supplementary concepts

  • CHOP protocol
  • MINE-ESHAP protocol